# Drug-Induced Liver Injury (DILI) Causality Assessment Report: Tofacitinib

**Date:** 2025-09-13T09-07-26

---

## Table of Contents
1. [Executive Summary](#executive-summary)
2. [Background on Tofacitinib](#background-on-tofacitinib)
3. [Case Data Summary](#case-data-summary)
4. [Causality Assessment Framework](#causality-assessment-framework)
5. [Evidence Supporting Causality](#evidence-supporting-causality)
6. [LiverTox Classification and Likelihood Score](#livertox-classification-and-likelihood-score)
7. [Limitations in Current Assessment](#limitations-in-current-assessment)
8. [Recommendations](#recommendations)
9. [Sources](#sources)

---

## Executive Summary

This report presents a causality assessment of drug-induced liver injury (DILI) potentially associated with tofacitinib use in a female patient. Due to critical missing clinical, laboratory, and virological data, a formal causality score (e.g., RECAM) could not be computed. Based on available scientific literature and authoritative resources such as LiverTox (National Institutes of Health, updated April 25, 2025), tofacitinib is classified as a suspected but unproven rare cause of clinically apparent liver injury (Likelihood Score: E*). While transient, asymptomatic aminotransferase elevations are common, no well-documented cases of severe hepatotoxicity or acute liver failure have been confirmed in clinical trials or large post-marketing studies. Reactivation of hepatitis B remains a potential risk in susceptible patients, though not observed in this case due to lack of virological data.

---

## Background on Tofacitinib

Tofacitinib is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis (LiverTox, 2025). It functions by inhibiting JAK1 and JAK3, thereby modulating immune signaling pathways. Common side effects include infections, neutropenia, headache, and mild-to-moderate elevations in serum aminotransferases.

- **Metabolism**: Primarily hepatic via CYP3A4, rendering it susceptible to drug-drug interactions and potential generation of reactive metabolites (LiverTox, 2025).
- **Hepatic Safety Profile**: In clinical trials, 28–34% of patients experienced ALT/AST elevations, typically mild and transient. Elevations >3x ULN occurred in 1–2% of cases, rarely leading to discontinuation (Kremer et al., 2009; Tanaka et al., 2011).
- **Clinically Apparent Liver Injury**: No confirmed cases reported in pre-licensure trials or large-scale post-marketing analyses (LiverTox, 2025; Hoisnard et al., 2022).

---

## Case Data Summary

The available case data is severely limited, precluding formal quantitative causality assessment:

- **Demographics**: Female patient; no age, weight, or comorbidities provided.
- **Liver Enzymes**: All values (ALT, AST, ALP, bilirubin) and baseline levels missing.
- **Temporal Data**: Onset after drug initiation or cessation unknown.
- **Dechallenge/Rechallenge**: No data available.
- **Virology & Autoimmunity**: All markers (HAV, HBV, HCV, HEV, CMV, EBV, HSV, ANA, ASMA, IgG) missing.
- **Imaging & Biopsy**: No imaging or histological data available.
- **Alcohol Use**: 0 standard drinks per day.
- **RECAM Score**: Indeterminate due to insufficient data across all domains.
- **LiverTox Category**: D (Drugs with little or no evidence of liver injury but potential for idiosyncratic reactions).

---

## Causality Assessment Framework

Causality assessment in DILI relies on structured frameworks such as:

- **RUCAM (Roussel Uclaf Causality Assessment Method)**: Requires temporal, biochemical, and exclusionary criteria.
- **RECAM (Refined Electronic Causality Assessment Method)**: Electronic adaptation requiring comprehensive lab, temporal, and exclusionary data.
- **LiverTox Likelihood Score**: Qualitative scoring system from A (Definite) to E (Unlikely), with E* indicating suspected but unproven rare cases.

In this case, the absence of key variables (enzyme trends, time to onset, dechallenge response, alternative etiology exclusion) renders RUCAM and RECAM scores incalculable.

---

## Evidence Supporting Causality

Despite missing case data, published evidence informs the causality context:

### 1. Biochemical Signal
- Tofacitinib frequently causes mild, asymptomatic ALT/AST elevations (28–34% in trials), typically resolving without intervention (LiverTox, 2025; Kremer et al., 2012).
- Elevations >3x ULN occur in 1–2% of patients; >5x ULN is rare and may warrant dose reduction (LiverTox, 2025).

### 2. Clinical Evidence
- No cases of Hy’s Law hepatotoxicity (ALT >3x ULN + bilirubin >2x ULN) reported in clinical trials (FDA NDA 213082, 2020).
- Post-marketing surveillance (n=6,194 patients over 8.5 years) reported hepatobiliary adverse events in only 0.12 per 100 patient-years (Cohen et al., 2018).
- One case report described liver failure in an 18-year-old female on tofacitinib for alopecia areata, but confounding factors and lack of virology/autoimmune workup limit causal attribution (PubMed, 2023).

### 3. Mechanistic Plausibility
- Metabolism via CYP3A4 may generate reactive intermediates, though direct hepatotoxicity remains unproven (LiverTox, 2025).
- Immunosuppressive effects may permit viral reactivation (e.g., HBV), particularly in HBsAg+ patients not on prophylaxis (Chen et al., 2018; Wang et al., 2021).

### 4. Exclusion of Alternatives
- No data available to exclude viral hepatitis, autoimmune hepatitis, ischemic injury, or biliary obstruction — all common mimics of DILI.
- Alcohol use is ruled out (0 drinks/day).

---

## LiverTox Classification and Likelihood Score

According to the NIH LiverTox database (updated April 25, 2025):

> **Likelihood Score: E*** — *Suspected but unproven rare cause of clinically apparent liver injury with the potential to cause reactivation of hepatitis B.* (LiverTox, 2025)

This classification is based on:
- Biochemical signals (transaminase elevations) without histologic or clinical injury.
- Absence of published, well-documented cases meeting standard DILI criteria.
- Theoretical risk based on metabolic pathway and immunosuppression.

---

## Limitations in Current Assessment

The inability to compute a causality score or reach a definitive conclusion stems from:

- **Missing Laboratory Data**: No baseline or peak values for ALT, AST, ALP, or bilirubin.
- **No Temporal Data**: Unknown time from drug initiation to potential liver injury onset.
- **Incomplete Exclusion Workup**: All viral serologies, autoimmune markers, and imaging studies missing.
- **No Histology**: Liver biopsy data absent to confirm or refute DILI pattern.
- **No Rechallenge/Dechallenge Information**: Critical for establishing temporal relationship.

Without these elements, any causality assertion remains speculative.

---

## Recommendations

> **1. Complete Diagnostic Workup**  
> Obtain full liver panel (ALT, AST, ALP, GGT, bilirubin, albumin, INR), viral hepatitis serologies (HAV IgM, HBsAg, anti-HBc, anti-HCV, HEV IgM), autoimmune markers (ANA, ASMA, IgG), and imaging (ultrasound or MRCP) to exclude alternative etiologies.

> **2. Monitor Liver Enzymes Closely**  
> If tofacitinib is continued, monitor ALT/AST every 4–8 weeks. Discontinue or reduce dose if ALT/AST rise >5x ULN or if accompanied by jaundice (LiverTox, 2025).

> **3. Screen for Hepatitis B Prior to Therapy**  
> All patients starting tofacitinib should be tested for HBsAg and anti-HBc. HBsAg+ patients require antiviral prophylaxis (e.g., entecavir or tenofovir) (LiverTox, 2025; Mohareb et al., 2022).

> **4. Avoid Rechallenge Without Clear Indication**  
> Given the immunosuppressive nature of tofacitinib and potential idiosyncratic risk, rechallenge should only occur if benefits outweigh risks and under strict monitoring.

> **5. Report to Pharmacovigilance Databases**  
> Submit this case to national or international pharmacovigilance systems (e.g., WHO VigiBase, FDA FAERS) to contribute to post-marketing surveillance.

---

## Sources

1. **LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — Tofacitinib**  
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health.  
   https://www.ncbi.nlm.nih.gov/books/NBK547848/  
   (LiverTox, 2025)

2. **Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.**  
   *Arthritis Rheum.* 2009;60(7):1895–905.  
   (Kremer et al., 2009)

3. **Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.**  
   *Arthritis Care Res (Hoboken).* 2011;63(8):1150–8.  
   (Tanaka et al., 2011)

4. **Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5+ years: integrated analysis of data from the global clinical trials.**  
   *Ann Rheum Dis.* 2017;76(7):1253–62.  
   (Cohen et al., 2017)

5. **Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study.**  
   *Ann Rheum Dis.* 2018;77(5):780–2.  
   (Chen et al., 2018)

6. **Wang ST, Tseng CW, Hsu CW, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.**  
   *Int J Rheum Dis.* 2021;24(10):1362–9.  
   (Wang et al., 2021)

7. **Hoisnard L, Lebrun-Vignes B, Maury S, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.**  
   *Sci Rep.* 2022;12:7140.  
   (Hoisnard et al., 2022)

8. **Mohareb AM, Patel NJ, Fu X, et al. Screening for hepatitis B virus prior to initiating tocilizumab and tofacitinib in patients with rheumatic diseases: a cross-sectional study.**  
   *J Rheumatol.* 2022;49(1):104–9.  
   (Mohareb et al., 2022)

9. **Drug-induced liver injury due to tofacitinib: a case report.**  
   *J Med Case Rep.* 2023;17:90.  
   https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-023-03821-4  
   (PubMed, 2023)

10. **FDA NDA 213082 Multidiscipline Review.**  
    U.S. Food and Drug Administration.  
    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213082Orig1s000MultidisciplineR.pdf  
    (FDA, 2020)